Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development
Journal of Neuropathology & Experimental Neurology · 2025
DOI: 10.1093/jnen/nlaf071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2025. Verfasst von Yara Al Ojaimi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032, Tours, France. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Région Centre Val de Loire, French National Research Agency, ARSLA.
Abstract (Originalsprache)
Identifying disease-related molecular signatures that can be used as biomarkers is critical for the development of preclinical therapies for amyotrophic lateral sclerosis (ALS). In this study, we focused on the Prp-TDP-43A315T transgenic mouse model of ALS to explore peripheral and central molecular alterations associated with disease progression. Prp-TDP-43A315T transgenic (Tg) and C57BL/6J wild-type mice were monitored from 50 to 400 postnatal days. One cohort assessed phenotypic parameters and MRI activity at 3 timepoints, ie, before (T0), at disease onset (T1), and at end-stage (T2). A second cohort validated findings from the first using omics analyses of tissues to examine ALS-related markers. Tg mice showed reduced body weight, decreased grip strength and tail position, and increased gait impairment at T1. Changes in (p)TDP-43, NRF2, GFAP, and pAMPK expression were noted in brain samples from the second cohort at T1. Metabolomic and lipidomic analyses revealed shifts in specific molecules in the brain and muscle of Tg mice. These data highlight individual differences in ALS pathology and adaptive responses to TDP-43-induced damage. This model provides valuable insights into TDP-43 proteinopathies and presents an innovative method for analyzing pathophysiological pathways through dried blood spot analysis, thereby expanding its applicability across various research fields.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032, Tours, France.
- CHU de Tours, Service de Biochimie et Biologie Moléculaire, Tours, France.
- CHU de Tours, Service de Médecine Nucléaire In Vitro, Tours, France.
- CBM, Orléans, France.
- CHU de Tours, Service de Neurologie, Tours, France.
- Key-Obs, Orléans, France.
ORCID-Profile: Hélène Blasco
Förderung
- Région Centre Val de Loire
- French National Research Agency
- ARSLA
Zitieren
APA
Al Ojaimi, Y., Osman, S., Alarcan, H., Emond, P., Veyrat-Durebex, C., Lanznaster, D., Meme, S., Clemencon, R., Galineau, L., Corcia, P., Andres, C., Vourc'h, P., Masse, F., Trovero, F., & Blasco, H. (2025). Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlaf071
Vancouver
Al Ojaimi Y, Osman S, Alarcan H, Emond P, Veyrat-Durebex C, Lanznaster D, et al. Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development. Journal of Neuropathology & Experimental Neurology. 2025. doi:10.1093/jnen/nlaf071
BibTeX
@article{AlOjaimi2025,
author = {Al Ojaimi, Yara and Osman, Samira and Alarcan, Hugo and Emond, Patrick and Veyrat-Durebex, Charlotte and Lanznaster, Debora and Meme, Sandra and Clemencon, Rudy and Galineau, Laurent and Corcia, Philippe and Andres, Christian and Vourc'h, Patrick and Masse, Fabienne and Trovero, Fabrice and Blasco, Hélène},
title = {Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2025},
doi = {10.1093/jnen/nlaf071}
}
EUVIMED